MindMed (MNMD) IPO on Nasdaq: Becomes Second Public Psychedelic Company.
InvestmentU
By Amber Deter
Apr 27, 2021 at 12:55PM
The MindMed IPO is making...
Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company
WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE
What exactly is a favorite?
First...
Huge News at Ehave Inc.(EHVVF), our Favorite Psychedelic.
We just finished compiling the 2021 Psychedelic Investor Guide and reviewed 44 companies - in all shapes and sizes. Excluding Johnson &...
Cybin (CLXPF CYBN) Banks $30 Million Overnight.
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares.
LIVE QUOTE
Incredible Ibogaine Psychedelic’s Testimonial
TIME MAGAZINEIn 2013, Marcus retired from the military. But life as a civilian only made his depression, anger, headaches, anxiety, alcoholism, impulsivity...
Are Psychedelics the New Prozac?
Amidst a national epidemic of opioid abuse, and suicides the need for new therapeutics has gained greater urgency. In it's first step to...
Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.
Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target.
Atai Life Sciences (ATAI) Founder Christian Angermayer Interview.(VIDEO)
Best Psychedelic related interview we've seen yet. Christian states, "I think ultimately, the total addressable market is 100% of the world population!"
I Use Ketamine for Depression – Here’s How It Works.
FREETHINK: When first manufactured as an anesthetic for humans and animals in 1962, doctors had no intention of prescribing ketamine for depression....
Ehave (EHVVF) Looks to Power the Psychedelics Revolution
Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days...
Latest article
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio...
Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.
Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
